300 related articles for article (PubMed ID: 9028722)
21. Pramlintide: A new tool in diabetes management.
Want LL; Ratner RE
Curr Diab Rep; 2006 Nov; 6(5):344-9. PubMed ID: 17076994
[TBL] [Abstract][Full Text] [Related]
22. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
[TBL] [Abstract][Full Text] [Related]
23. Modulation of gastric emptying as a therapeutic approach to glycaemic control.
Moyses C; Young A; Kolterman O
Diabet Med; 1996 Sep; 13(9 Suppl 5):S34-8. PubMed ID: 8894469
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of gastric emptying.
Young A
Adv Pharmacol; 2005; 52():99-121. PubMed ID: 16492543
[TBL] [Abstract][Full Text] [Related]
25. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.
Thompson RG; Pearson L; Kolterman OG
Diabetologia; 1997 Nov; 40(11):1278-85. PubMed ID: 9389419
[TBL] [Abstract][Full Text] [Related]
26. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.
Thompson RG; Peterson J; Gottlieb A; Mullane J
Diabetes; 1997 Apr; 46(4):632-6. PubMed ID: 9075803
[TBL] [Abstract][Full Text] [Related]
27. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia.
Deane AM; Chapman MJ; Fraser RJ; Summers MJ; Zaknic AV; Storey JP; Jones KL; Rayner CK; Horowitz M
Crit Care Med; 2010 May; 38(5):1261-9. PubMed ID: 20228679
[TBL] [Abstract][Full Text] [Related]
28. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
[TBL] [Abstract][Full Text] [Related]
29. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
Samsom M; Szarka LA; Camilleri M; Vella A; Zinsmeister AR; Rizza RA
Am J Physiol Gastrointest Liver Physiol; 2000 Jun; 278(6):G946-51. PubMed ID: 10859225
[TBL] [Abstract][Full Text] [Related]
30. Pramlintide in the treatment of diabetes.
Edelman SV; Darsow T; Frias JP
Int J Clin Pract; 2006 Dec; 60(12):1647-53. PubMed ID: 17109671
[TBL] [Abstract][Full Text] [Related]
31. Gastric emptying and postprandial glucose excursions in adolescents with type 1 diabetes.
Heptulla RA; Rodriguez LM; Mason KJ; Haymond MW
Pediatr Diabetes; 2008 Dec; 9(6):561-6. PubMed ID: 18761650
[TBL] [Abstract][Full Text] [Related]
32. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
Chapman I; Parker B; Doran S; Feinle-Bisset C; Wishart J; Lush CW; Chen K; Lacerte C; Burns C; McKay R; Weyer C; Horowitz M
Obesity (Silver Spring); 2007 May; 15(5):1179-86. PubMed ID: 17495194
[TBL] [Abstract][Full Text] [Related]
33. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
[TBL] [Abstract][Full Text] [Related]
34. Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes.
Riddle MC; Yuen KC; de Bruin TW; Herrmann K; Xu J; Öhman P; Kolterman OG
Diabetes Obes Metab; 2015 Sep; 17(9):904-7. PubMed ID: 26040429
[TBL] [Abstract][Full Text] [Related]
35. Clinical studies.
Young A
Adv Pharmacol; 2005; 52():289-320. PubMed ID: 16492555
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
King AB
Diabetes Technol Ther; 2010 Feb; 12(2):105-8. PubMed ID: 20105039
[TBL] [Abstract][Full Text] [Related]
37. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.
Chapman I; Parker B; Doran S; Feinle-Bisset C; Wishart J; Strobel S; Wang Y; Burns C; Lush C; Weyer C; Horowitz M
Diabetologia; 2005 May; 48(5):838-48. PubMed ID: 15843914
[TBL] [Abstract][Full Text] [Related]
38. Optimizing diabetes treatment using an amylin analogue.
Edelman SV
Diabetes Educ; 2008; 34 Suppl 1():4S-10S. PubMed ID: 18268000
[TBL] [Abstract][Full Text] [Related]
39. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal.
Frost GS; Brynes AE; Dhillo WS; Bloom SR; McBurney MI
Eur J Clin Nutr; 2003 Feb; 57(2):293-8. PubMed ID: 12571662
[TBL] [Abstract][Full Text] [Related]
40. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.
Kolterman OG
Diabet Med; 1997 Jun; 14 Suppl 2():S35-8. PubMed ID: 9212328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
